Medtronic Pays $43M To Settle Shareholder Suit Over Infuse Bone Graft Studies
MINNEAPOLIS — Medtronic Inc. and four individual defendants on July 1 agreed to a $43 million class settlement involving alleged securities violations related to Medtronic’s reporting of risks with the Infuse...To view the full article, register now.
Already a subscriber? Click here to view full article